Core Points - Xenon Pharmaceuticals Inc. has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution effective June 27, 2025 [1] - The Russell 3000® Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization, while the Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. indexes, making them widely used by investment managers and institutional investors [3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics [4] - The company is advancing an ion channel product portfolio to address high unmet medical needs, including epilepsy and depression [4] - Azetukalner, a novel and highly potent selective Kv7 potassium channel opener, is the most advanced clinically validated potassium channel modulator in late-stage clinical development for multiple indications [4]

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need [2] - The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression [2] - Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications [2] Event Announcement - Xenon Pharmaceuticals will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL, from June 9-11, 2025 [1] - The fireside chat presentation is scheduled for June 10, 2025, from 3:20-3:55 PM Eastern Time, with Ian Mortimer, President and CEO, as the presenter [1] - A live audio webcast of the presentation will be available on the "Investors" section of Xenon's website and will be posted for replay following the event [1]

Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need [3] - The company is advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression [3] - Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, is highlighted as the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications [3] Event Participation - Xenon Pharmaceuticals will present at the 2025 RBC Capital Markets Global Healthcare Conference in New York, NY, on May 20-21, 2025 [1] - The presentation will take place on May 21, 2025, from 10:30-10:55 AM Eastern Time, featuring Ian Mortimer, President and Chief Executive Officer [2] - A live audio webcast of the presentation will be available on the "Investors" section of Xenon's website and will be posted for replay following the event [2]

Core Viewpoint - Xenon Pharmaceuticals Inc. is set to report its first quarter 2025 financial results and provide a business update on May 12, 2025, after the U.S. financial markets close [1]. Group 1: Financial Reporting - The financial results and business update will be announced after the close of U.S. financial markets on May 12, 2025 [1]. - A conference call and webcast will take place on the same day at 4:30 pm Eastern Time [2]. Group 2: Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for conditions such as epilepsy and depression [3]. - The company is advancing an ion channel product portfolio, with Azetukalner being the most advanced potassium channel modulator in late-stage clinical development [3].